Scholarlink

Background <p>For infants aged ≤ 60-days evaluated for temperature instability, we sought to ascertain if use of a multiplex meningoencephalitis panel (MEP) decreased length of hospital stay (LOS), antimicrobial length of therapy (LoT), and use of other molecular testing.</p> Methods <p>This was a retrospective cohort study of infants aged ≤ 60-days hospitalized for temperature instability between 1/2012 and 1/2022. Patients were included if blood and cerebrospinal fluid (CSF) cultures were negative for bacterial infection. Patients were categorized into groups by MEP availability and use. LOS, LoT, and use of other molecular tests were compared by MEP usage group.</p> Results <p>A total of 2076 patients met study criteria; there was no difference between groups regarding sex, race, ethnicity, or age at admission. During the period of MEP availability (2017–2022), the test was performed for 156/1101 (14%) patients. Compared to eligible patients without the MEP performed, MEP use was associated with longer LOS (57.7 vs. 47.3&#xa0;h, <i>p</i> &lt; 0.0001) and longer LoT (37.4 vs. 35.5&#xa0;h, <i>p</i> &lt; 0.0001). Use of the MEP was also associated with performance of additional molecular tests. Patients with CSF obtained after antimicrobial initiation had longer LOS compared to those with CSF obtained before antimicrobials were initiated, and MEP use did not mitigate that.</p> Conclusions <p>Young infants without bacterial infection by blood or CSF culture that had the MEP performed had longer length of hospital stays, longer duration of antimicrobial therapy, and more molecular testing performed compared to those without the MEP performed. Further research focusing on clinical scenarios where MEP use may be most beneficial for infants with temperature instability is needed.</p> Clinical trial <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Utility of the meningoencephalitis panel in management of neonates with temperature instability

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • Brittany Player,
  • Peter L. Havens,
  • Michelle L. Mitchell,
  • Sheila Swartz,
  • Amy Y. Pan,
  • Sai Alekha Challa,
  • Glenn Bushee,
  • Anna R. Huppler

摘要

Background

For infants aged ≤ 60-days evaluated for temperature instability, we sought to ascertain if use of a multiplex meningoencephalitis panel (MEP) decreased length of hospital stay (LOS), antimicrobial length of therapy (LoT), and use of other molecular testing.

Methods

This was a retrospective cohort study of infants aged ≤ 60-days hospitalized for temperature instability between 1/2012 and 1/2022. Patients were included if blood and cerebrospinal fluid (CSF) cultures were negative for bacterial infection. Patients were categorized into groups by MEP availability and use. LOS, LoT, and use of other molecular tests were compared by MEP usage group.

Results

A total of 2076 patients met study criteria; there was no difference between groups regarding sex, race, ethnicity, or age at admission. During the period of MEP availability (2017–2022), the test was performed for 156/1101 (14%) patients. Compared to eligible patients without the MEP performed, MEP use was associated with longer LOS (57.7 vs. 47.3 h, p < 0.0001) and longer LoT (37.4 vs. 35.5 h, p < 0.0001). Use of the MEP was also associated with performance of additional molecular tests. Patients with CSF obtained after antimicrobial initiation had longer LOS compared to those with CSF obtained before antimicrobials were initiated, and MEP use did not mitigate that.

Conclusions

Young infants without bacterial infection by blood or CSF culture that had the MEP performed had longer length of hospital stays, longer duration of antimicrobial therapy, and more molecular testing performed compared to those without the MEP performed. Further research focusing on clinical scenarios where MEP use may be most beneficial for infants with temperature instability is needed.

Clinical trial

Not applicable.